These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2116044)

  • 1. The maximum medical aid price programme. A review of the concept and of its ability to reduce expenditure on medicines.
    Boyce D; Bartlett G
    S Afr Med J; 1990 Aug; 78(3):147-51. PubMed ID: 2116044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Containing medicines costs in the private sector--the example of a medical benefit scheme.
    Hukins G; Boyce D
    S Afr Med J; 1990 Aug; 78(3):152-4. PubMed ID: 2116045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for managing prescription drug costs.
    Stern L
    Bus Health; 1990 Jun; 8(6):41-2, 44. PubMed ID: 10104793
    [No Abstract]   [Full Text] [Related]  

  • 4. Experience of a medicines reference-pricing model.
    Rothberg AD; Blignault J; Serfontein CB; Valodia B; Eekhout S; Pels LM
    S Afr Med J; 2004 Mar; 94(3):183-8. PubMed ID: 15098277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
    Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
    Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
    Morgan SG; Agnew JD; Barer ML
    Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of prescribing patterns and consequent costs at Alexandra Health Centre and in the private fee-for-service medical aid sector.
    Price MR
    S Afr Med J; 1990 Aug; 78(3):158-60. PubMed ID: 2377947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent trends in drug prescribing rates and costs in New Zealand.
    Malcolm LA; Mehl A
    N Z Med J; 1988 May; 101(845):233-6. PubMed ID: 3368132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of medicine.
    Silk AD
    West J Med; 1990 Jan; 152(1):75-6. PubMed ID: 2309481
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
    Lee IH; Bloor K; Hewitt C; Maynard A
    Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economics of drug prescribing in Ireland.
    O'Hanrahan M; O'Malley K
    Ir Med J; 1981 Oct; 74(10):309-10, 312. PubMed ID: 7309452
    [No Abstract]   [Full Text] [Related]  

  • 18. Reasons why insured consumers co-pay for medicines at retail pharmacies in Pretoria, South Africa.
    Mpanza NM; Bradley H; Laing R
    Afr J Prim Health Care Fam Med; 2019 Mar; 11(1):e1-e6. PubMed ID: 31038333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community drug expenditure and recent cost containment measures.
    Walshe V; Kenneally M
    Ir Med J; 2013 Feb; 106(2):44-6. PubMed ID: 23472384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing prescription drug costs: a case study.
    DuBois RW; Feinberg PE
    Med Interface; 1994 Jun; 7(6):65-8, 70, 74. PubMed ID: 10135321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.